- Monoclonal Antibodies,
- Immunosuppressive Drugs,
- Steroids,
- TNF Inhibitors,
- Tyrosine Kinase Inhibitors
- Others
Graft Vs Host Disease Treatment Market size was valued at USD x million in 2022 and is poised to grow at a CAGR of 7.08% from 2023-2029. Graft versus host disease is an immune-mediated disease. It is a medical complication in which there is a complex interaction between the donor and the adaptive immunity of the recipient. The disease occurs when the bone marrow or the stem cells are transplanted. The treatment using stem cells and bone marrow is used in the reconstruction of the damaged cells that surround the cancer cells. It is also used during solid organ transplantation. The chances of developing graft versus host disease are more in allogeneic transplantation.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Growing Number of Pipeline Drugs and Increasing Rate of Bone Marrow or Hematopoietic Stem Cell Treatment can drive the global Graft vs Host Disease Treatment market growth over the forecast years.
The global Graft vs Host Disease Treatment market size is valued at USD 2,967.9 million in 2022
The major market players are Pfizer Inc., Novartis, Abbvie Inc., Sanofi (Kadmon Pharmaceuticals), Sanofi (Genzyme), Incyte Corporation, Bristol Myers Squibb Company, Genentech Inc., Astellas Pharma US Inc., and others.
The graft vs host disease treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Graft vs Host Disease Treatment Market Introduction |
2.1. Global Graft vs Host Disease Treatment Market Taxonomy |
2.2. Global Graft vs Host Disease Treatment Market Definitions |
2.2.1. By Drug Class |
2.2.2. By Disease Type |
2.2.3. By Route of Administration |
2.2.4. By Distribution Channel |
2.2.5. By Region |
3. Global Graft vs Host Disease Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Graft vs Host Disease Treatment Market Dynamic Factors - Impact Analysis |
3.6. Global Graft vs Host Disease Treatment Market Competition Landscape |
4. Global Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Graft vs Host Disease Treatment Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1. Monoclonal Antibodies |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Immunosuppressive Drugs |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Steroids |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. TNF Inhibitors |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Tyrosine Kinase Inhibitors |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Graft vs Host Disease Treatment Market, By Disease Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1. Acute Graft vs Host Disease |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Chronic Graft vs Host Disease |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Graft vs Host Disease Treatment Market, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1. Oral |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Graft vs Host Disease Treatment Market, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Graft vs Host Disease Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.1. North America |
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Region, 2023 - 2029 |
10. North America Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Monoclonal Antibodies |
10.1.2. Immunosuppressive Drugs |
10.1.3. Steroids |
10.1.4. TNF Inhibitors |
10.1.5. Tyrosine Kinase Inhibitors |
10.1.6. Others |
10.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Acute Graft vs Host Disease |
10.2.2. Chronic Graft vs Host Disease |
10.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Oral |
10.3.2. Parenteral |
10.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospital Pharmacies |
10.4.2. Retail Pharmacies |
10.4.3. Online Pharmacies |
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. USA |
10.5.2. Canada |
10.6. North America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029 |
10.7. North America Graft vs Host Disease Treatment Market Dynamics Trends |
11. Europe Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Monoclonal Antibodies |
11.1.2. Immunosuppressive Drugs |
11.1.3. Steroids |
11.1.4. TNF Inhibitors |
11.1.5. Tyrosine Kinase Inhibitors |
11.1.6. Others |
11.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Acute Graft vs Host Disease |
11.2.2. Chronic Graft vs Host Disease |
11.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Oral |
11.3.2. Parenteral |
11.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospital Pharmacies |
11.4.2. Retail Pharmacies |
11.4.3. Online Pharmacies |
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Spain |
11.5.5. Italy |
11.5.6. Russia |
11.5.7. Rest of Europe |
11.6. Europe Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029 |
11.7. Europe Graft vs Host Disease Treatment Market Dynamics Trends |
12. Asia-Pacific Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Monoclonal Antibodies |
12.1.2. Immunosuppressive Drugs |
12.1.3. Steroids |
12.1.4. TNF Inhibitors |
12.1.5. Tyrosine Kinase Inhibitors |
12.1.6. Others |
12.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Acute Graft vs Host Disease |
12.2.2. Chronic Graft vs Host Disease |
12.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Oral |
12.3.2. Parenteral |
12.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospital Pharmacies |
12.4.2. Retail Pharmacies |
12.4.3. Online Pharmacies |
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. China |
12.5.2. India |
12.5.3. Japan |
12.5.4. ASEAN |
12.5.5. Australia & New Zealand |
12.5.6. Rest of Asia-Pacific |
12.6. Asia-Pacific Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029 |
12.7. Asia-Pacific Graft vs Host Disease Treatment Market Dynamics Trends |
13. Latin America Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
13.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Monoclonal Antibodies |
13.1.2. Immunosuppressive Drugs |
13.1.3. Steroids |
13.1.4. TNF Inhibitors |
13.1.5. Tyrosine Kinase Inhibitors |
13.1.6. Others |
13.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Acute Graft vs Host Disease |
13.2.2. Chronic Graft vs Host Disease |
13.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Oral |
13.3.2. Parenteral |
13.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospital Pharmacies |
13.4.2. Retail Pharmacies |
13.4.3. Online Pharmacies |
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Mexico |
13.5.3. Rest of Latin America |
13.6. Latin America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029 |
13.7. Latin America Graft vs Host Disease Treatment Market Dynamics Trends |
14. Middle East and Africa Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
14.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Monoclonal Antibodies |
14.1.2. Immunosuppressive Drugs |
14.1.3. Steroids |
14.1.4. TNF Inhibitors |
14.1.5. Tyrosine Kinase Inhibitors |
14.1.6. Others |
14.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Acute Graft vs Host Disease |
14.2.2. Chronic Graft vs Host Disease |
14.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Oral |
14.3.2. Parenteral |
14.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospital Pharmacies |
14.4.2. Retail Pharmacies |
14.4.3. Online Pharmacies |
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Gulf Cooperation Council (GCC) Countries |
14.5.2. South Africa |
14.5.3. Rest of MEA |
14.6. MEA Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029 |
14.7. MEA Graft vs Host Disease Treatment Market Dynamics Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. F. Hoffmann-La Roche Ltd. |
15.2.2. AbbVie, Inc. |
15.2.3. Bristol-Myers Squibb |
15.2.4. Pfizer, Inc. |
15.2.5. Baxter International plc |
15.2.6. Novartis AG |
15.2.7. Eli Lilly and Co. |
15.2.8. Shire plc |
15.2.9. Alleran plc |
15.2.10. Caladrius |
15.2.11. Eisai |
15.2.12. Anterogen |
16. Research Methodology |
17. Key Assumptions and Acronyms |